摘要
目的 探讨脂肪酸合成酶 (FASE)、HER 2 /neu、bcl 2和p5 3在Ⅰ期非小细胞肺癌(NSCLC)中的表达及其预后意义。方法 采用免疫组织化学法 ,对 84例Ⅰ期肺癌手术标本进行FASE、HER 2 /neu、bcl 2和p5 3蛋白的检测 ,分析各标志物与多种临床因素及预后的关系。结果FASE、HER 2 /neu、bcl 2和p5 3在Ⅰ期NSCLC中的阳性表达率分别为 2 9.8%、4 0 .5 %、33.3%和 39.3%。FASE阳性和阴性患者的术后局部复发率分别为 2 8.0 %和 10 .2 % ,差异有显著性 (P =0 .0 5 0 ) ;骨转移率分别为 6 1.5 %和 2 3.9% ,差异有极显著性 (P =0 .0 0 7)。HER 2 /neu阳性和阴性患者的 5年生存率分别为 37.7%和 6 7.7% (P =0 .0 0 8) ,FASE阳性和阴性患者的 5年生存率分别为 35 .1%和 6 6 .1% ,差异均有极显著性 (P均 =0 .0 0 8) ,表明HER 2 /neu和FASE的表达与预后明显相关。HER 2 /neu和FASE均为阴性的患者 5年生存率为 78.2 % ,均为阳性的患者 5年生存率为 36 .3% ,差异有极显著性(P =0 .0 0 2 )。然而 ,bcl 2和p5 3未发现有临床预后意义。结论 HER 2 /neu和FASE是Ⅰ期非小细胞肺癌的独立预后因素 ,HER 2
Objective To evaluate the prognostic value of expression of fatty acid synthase (FASE), HER 2/neu, bcl 2 and p53 in stage Ⅰ non small cell lung cancer(NSCLC). Methods Expression of FASE, HER 2/neu, bcl 2 and p53 protein was detected by immunohistochemical staining in 84 patients with stage Ⅰ NSCLC who underwent surgery. Multiple clinical parameters and survival were analyzed. Results The expression of FASE, HER 2/neu, bcl 2 and p53 was 29.8%,40.5%,33.3% and 39.3%,respectively. The local recurrence and bone metastasis rate were higher in FASE positive patients than in negative patients (28.0% vs 10.2%, P =0.05; 61.5% vs 23.9%, P =0.017, respectively). The 5 year survival rate was lower in HER 2/neu and FASE positive patients than in negative patients (37.7% vs 67.7%, P =0.0083; 35.1% vs 66.1% , P =0.0079, respectively), which showed that HER 2/neu and FASE expression were associated with significantly poor survival. Patients whose tumors were both HER 2/neu and FASE negative had better outcome, with a 5 year survival rate of 78.2%, compared with 36.3% in those whose tumors were positive for either one ( P =0.002). However, bcl 2 and p53 were not independent prognostic factors for survival. Conclusion HER 2/neu and FASE are independent prognostic factor in stage Ⅰ non small cell lung cancer patients who expressed one or both markers.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2004年第6期369-372,共4页
Chinese Journal of Oncology
